Treating Cancer Drug Resistance May Come at a Cost to Immune System, Study Suggests
Inhibiting the key gene involved in cancer drug resistance could dull the anti-cancer immune response by inhibiting a type of T lymphocytes, a study from Sundrud lab finds.